Skip to main content
Open Access Publications from the University of California


UCLA Previously Published Works bannerUCLA

An engineered human Fc domain that behaves like a pH-toggle switch for ultra-long circulation persistence.

  • Author(s): Lee, Chang-Han;
  • Kang, Tae Hyun;
  • Godon, Ophélie;
  • Watanabe, Makiko;
  • Delidakis, George;
  • Gillis, Caitlin M;
  • Sterlin, Delphine;
  • Hardy, David;
  • Cogné, Michel;
  • Macdonald, Lynn E;
  • Murphy, Andrew J;
  • Tu, Naxin;
  • Lee, Jiwon;
  • McDaniel, Jonathan R;
  • Makowski, Emily;
  • Tessier, Peter M;
  • Meyer, Aaron S;
  • Bruhns, Pierre;
  • Georgiou, George
  • et al.

The pharmacokinetic properties of antibodies are largely dictated by the pH-dependent binding of the IgG fragment crystallizable (Fc) domain to the human neonatal Fc receptor (hFcRn). Engineered Fc domains that confer a longer circulation half-life by virtue of more favorable pH-dependent binding to hFcRn are of great therapeutic interest. Here we developed a pH Toggle switch Fc variant containing the L309D/Q311H/N434S (DHS) substitutions, which exhibits markedly improved pharmacokinetics relative to both native IgG1 and widely used half-life extension variants, both in conventional hFcRn transgenic mice and in new knock-in mouse strains. engineered specifically to recapitulate all the key processes relevant to human antibody persistence in circulation, namely: (i) physiological expression of hFcRn, (ii) the impact of hFcγRs on antibody clearance and (iii) the role of competing endogenous IgG. DHS-IgG retains intact effector functions, which are important for the clearance of target pathogenic cells and also has favorable developability.

Many UC-authored scholarly publications are freely available on this site because of the UC's open access policies. Let us know how this access is important for you.

Main Content
For improved accessibility of PDF content, download the file to your device.
Current View